BBzP = Benzyl butyl phthalate; DCHP = Di-cyclo-hexyl phthalate; DEHP = Di-(2-ethylhexyl) phthalate; DEP = Di-ethyl phthalate; DiBP = Diisobutyl phthalate; DiNP = Di-iso-nonyl phthalate; DMP = Di-methyl phthalate; DnBP/DBP = Di-n-butyl phthalate; DnOP/DOP = Di-n-octyl phthalate; LOD = limit of detection, MBzP = Mono-benzyl phthalate; MCHP = Mono-cyclo-hexyl phthalate; MCPP = Mono-(3-carboxypropyl) phthalate; MECP = Mono-(2-ethyl-5-carboxylpentyl) phthalate; MEHHP = Mono-(2-ethyl-5-hydroxo-hexyl) phthalate; MEHP = Mono-(2-ethylhexyl) phthalate; MEOHP = Mono-(2-ethyl-5-oxohexyl) phthalate; MEP = Mono-ethyl phthalate; MiBP = Mono-isobutyl phthalate; MiNP = Mono-iso-nonyl phthalate; MMP = Mono-methyl phthalate; MnBP/MBP = Mono-n-butyl phthalate; MnOP/MOP = Mono-n-octyl phthalate. To develop a consensus definition of growth restriction in the newborn that can be used clinically to identify newborns at risk and in research to harmonize reporting and definition in the current absence of a gold standard.
CONSENSUS BASED DEFINITION OF GROWTH
Methods: An electronic-Delphi survey was performed among an international expert panel with standardized methods and predefined consensus rules. The panel consisted of leading pediatric specialists in the field. Responses were fed back at grouplevel and the list of participants was provided. Non-responders were excluded from subsequent rounds. In the first round, variables were scored on a 5-point Likert scale; in subsequent rounds, inclusion of variables and cut-offs were determined with a 70% level of agreement. In the final round participants selected the ultimate algorithm.
Results: In total, 57 experts participated in the first round; 79% completed the procedure. Mastitis is an inflammatory condition of the breast known to be associated with breastfeeding cessation. Specific probiotic bacteria may possess anti-inflammatory properties that support their potential use in preventing mastitis. The primary aim of the APProve trial was to evaluate the effectiveness of an oral probiotic for preventing mastitis in breastfeeding women.
Methods: APProve was a double-blind randomised controlled trial conducted in three NSW sites. Women who birthed at ≥37 weeks gestation and planning to breastfeed were consented and randomised within 72 hours of birth to either the probiotic (Lactobacillus Fermentum), or a placebo, taken daily for 8 weeks. The primary outcome was mastitis. Pre-specified secondary outcomes included treatment compliance, breastfeeding outcomes, and maternal and infant health.
Results: Of 639 women randomised, analysis of the primary outcome included 620 women, 311 in group "A" and 309 in group "B". Overall mastitis rate was 17.6%. Comparison between groups showed no difference in average maternal age (33.7 vs 33.2 years), proportion of women having a first baby (58.8% vs 56%), previous mastitis (12.2% vs 14.2%), caesarean section birth (27.7% vs 33%), fully breastfeeding at discharge (96.5% vs 97.1%) or antibiotics postpartum (10.3% vs 10.7%). Results for mastitis outcome will be presented by treatment allocation.
Conclusions: With increasing availability and marketing promoting the benefits of probiotics to health care workers and consumers, the APProve trial will provide important new knowledge about the effectiveness of probiotics in preventing mastitis. Implications for practice will be discussed. Left heart obstruction (LHO) is a common suspected diagnosis among neonates referred to the Newborn and Paediatric Emergency Transport (NETS) New South Wales (NSW) and can be difficult to differentiate from other causes of severe illness in the neonatal period.
TRANSPORT OF INFANTS WITH SUSPECTED LEFT HEART OBSTRUCTION: THE NETS NSW EXPERIENCE
Aims: To characterise the NETS NSW experience in managing infants with suspected and confirmed LHO, and to identify factors that distinguish infants with and without LHO during NETS telephone triage.
Methods: A retrospective, cohort study with review of prospectively collected NETS database records of infants with suspected or confirmed LHO during the 20-year epoch, 1996-2016.
Results: Of 329 eligible infants, 306 had confirmed LHO, of whom 85% were diagnosed accurately at the time of retrieval. 23 infants without LHO had alternative diagnoses of cardiac, respiratory, infective and metabolic conditions. 73.75% of the cohort was transported on treatment with prostaglandin E1 (PGE1). Presence of a cardiac murmur, cardiomegaly and hepatomegaly were significantly associated with a final diagnosis of LHO. Reduced or absent femoral pulses alone did not increase the likelihood of LHO. Degree of acidosis and impairment in oxygenation at referral did not predict LHO on univariate analysis, though these factors were significantly associated with suspicion of LHO at the time of NETS triage and likelihood of treatment with PGE1.
Conclusions: Differentiating LHO from other causes of severe illness in neonates is challenging. Clinical and x-ray findings may be more useful than blood gas markers in diagnosing LHO at triage. Institute, Auckland, New Zealand Email: b.bradford@auckland.ac.nz Background: Maternal perception of decreased fetal movement is associated with adverse pregnancy outcomes including stillbirth. We investigated the contribution of fetal movement quality and pattern to stillbirth risk.
MATERNAL PERCEPTION OF FETAL MOVEMENT QUALITY AND RISK OF LATE STILLBIRTH
Methods: We undertook a multicentre case-control study of potentially modifiable risk-factors for late stillbirth in New Zealand. Cases (n=164) had a non-anomalous singleton late stillbirth (≥28 weeks); controls (n=569) had ongoing pregnancies, matched by location and gestation. Data on perception of fetal movements in the two weeks before stillbirth/interview were collected via interviewer administered questionnaire. Outcomes are reported as adjusted odds ratio (aOR) for late stillbirth.
Results: In multivariable analyses, maternal perception of decreased frequency of fetal movement was associated with stillbirth (aOR 2.29, 95%CI 1.31-4.0). The majority of controls (74%) reported 'strong' fetal movement in the evening. Perception of 'quiet or light' movement in the evening, was associated with a greater than three-fold increased risk of late stillbirth (aOR 3.41, 95%CI 1.34-8.72). Perception of increased strength of fetal movements (aOR 0.20, 95% CI 0.12-0.35) was protective, as was perception of increased length of fetal movement clusters or 'busy times' (aOR 0.23, 95% CI 0.11-0.47), and daily perception of fetal hiccups (0.27, 95%CI 0.14-0.50).
Conclusions: Alterations in fetal movement quality and pattern are associated with stillbirth and should be considered when developing fetal movement screening protocols. Maternal perception of increasing strength of fetal movements is normal and suggests fetal wellbeing. Australian National University Medical School, Canberra, ACT, Australia, 2606 Email: Margaret.Broom@act.gov.au Background: To meet National Quality and Safety Standards we developed and validated a neonatal skin assessment tool to monitor pressure injuries in neonates. This tool identified nasal septal injury from nCPAP as the predominant pressure injury in neonates. Currently there is no literature comparing different CPAP interfaces and associated nasal injuries. The aim of our Quality Improvement Project was to determine and compare the incidence of nasal injuries using Fisher Paykel and Hudson interfaces with (WD) and without (WOD) the use of a duoderm nose.
INCIDENCE OF NASAL INJURY COMPARING FISHER PAYKEL AND HUDSON CPAP INTERFACES
Methods: A prospective observational study was undertaken in 2016-17. Both interfaces were used exclusively with and
